Weitz J, Koch M, Kienle P, Schrödel A, Willeke F, Benner A, Lehnert T, Herfarth C, von Knebel Doeberitz M
Division for Molecular Diagnostics and Therapy and the Division for Surgical Oncology, the Department of Surgery, University of Heidelberg, and the Central Unit Biostatistics, German Cancer Research Center, Heidelberg, Germany.
Ann Surg. 2000 Jul;232(1):66-72. doi: 10.1097/00000658-200007000-00010.
To determine the extent of pre- and intraoperative hematogenic tumor cell dissemination in patients undergoing liver resection for metastatic colorectal cancer.
For patients with hepatic metastases of colorectal cancer, liver resection is the only potentially curative therapy. However, 38% to 53% of patients develop extrahepatic tumor recurrence, probably caused by tumor cells disseminated before or during surgery not detected by current staging systems.
Blood samples harvested before, during, and after surgery from 41 patients and bone marrow samples from 30 patients undergoing resection of liver metastases of colorectal cancer were analyzed for disseminated tumor cells using cytokeratin 20 reverse transcriptase-polymerase chain reaction.
Tumor cells were detected in the blood samples of 26 of the 41 patients (63.4%) and in the bone marrow samples of 8 of the 30 patients (26.7%). Tumor cells were detected significantly more often during surgery than before or after surgery. Intraoperative tumor cell dissemination was detected in 41.7% of patients undergoing resection of two or more liver segments but only 14.3% of patients undergoing resection of one liver segment. Compared with resection of primary colorectal cancer, major liver resection carries an increased risk for intraoperative tumor cell dissemination.
Detection of disseminated tumor cells in patients undergoing liver resection for metastases of colorectal cancer using cytokeratin 20 reverse transcriptase-polymerase chain reaction might help to identify patients at high risk for tumor recurrence who may benefit from adjuvant therapy. Major liver resection of metastases leads to frequent intraoperative tumor cell shedding, possibly preventable by alternative surgical strategies.
确定接受转移性结直肠癌肝切除患者术前及术中血源性肿瘤细胞播散的程度。
对于结直肠癌肝转移患者,肝切除是唯一可能治愈的治疗方法。然而,38%至53%的患者会发生肝外肿瘤复发,这可能是由于当前分期系统未检测到的术前或术中播散的肿瘤细胞所致。
对41例接受结直肠癌肝转移切除术患者手术前、手术中和手术后采集的血样以及30例患者的骨髓样本,使用细胞角蛋白20逆转录聚合酶链反应分析播散性肿瘤细胞。
41例患者中有26例(63.4%)血样中检测到肿瘤细胞,30例患者中有8例(26.7%)骨髓样本中检测到肿瘤细胞。手术中检测到肿瘤细胞的频率明显高于手术前或手术后。在接受两个或更多肝段切除的患者中,41.7%检测到术中肿瘤细胞播散,而在接受一个肝段切除的患者中仅为14.3%。与原发性结直肠癌切除相比,肝大部切除术术中肿瘤细胞播散的风险增加。
使用细胞角蛋白20逆转录聚合酶链反应检测接受结直肠癌肝转移切除术患者的播散性肿瘤细胞,可能有助于识别有肿瘤复发高风险且可能从辅助治疗中获益的患者。肝转移瘤的肝大部切除术导致术中肿瘤细胞频繁脱落,采用替代手术策略可能可预防。